Loading stock data…
$70.74-1.32 (-1.83%)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
TransMedics Group, Inc. in the Healthcare sector is trading at $70.74 with a market capitalization of $3.0B. Wall Street consensus targets $98.73 (11 analysts), implying a +39.6% move over the next 12 months. The stock is currently near its 52-week low of $60.10, remaining 26.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $189.95M↑ | $173.93M↑ | $160.76M↑ | $143.82M↓ | $157.37M |
| Gross Profit | $113.20M↑ | $101.16M↑ | $93.41M↑ | $84.58M↓ | $96.59M |
| Operating Income | $23.74M↑ | $13.30M↓ | $21.27M↓ | $23.30M↓ | $36.57M |
| Net Income | $14.68M↑ | $7.32M↓ | $105.38M↑ | $24.32M↓ | $34.91M |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a po...